TCGA-OR-A5JQ-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Myxoid Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Myxoid Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Myxoid Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.441
- INFLAMMATORY_RESPONSE+0.401
- ANGIOGENESIS+0.397
- IL6_JAK_STAT3_SIGNALING+0.392
- KRAS_SIGNALING_UP+0.339
- PROTEIN_SECRETION+0.332
- INTERFERON_GAMMA_RESPONSE+0.317
- COAGULATION+0.272
- COMPLEMENT+0.241
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.414
- MYC_TARGETS_V1-0.341
- MYC_TARGETS_V2-0.331
- CHOLESTEROL_HOMEOSTASIS-0.282
- ADIPOGENESIS-0.276
- MTORC1_SIGNALING-0.248
- PEROXISOME-0.176
- FATTY_ACID_METABOLISM-0.172
- XENOBIOTIC_METABOLISM-0.165
- PANCREAS_BETA_CELLS-0.145
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303739 | — | — | 0.842 |
| 2 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.827 |
| 3 | MDT-AP-0390 | Med | Medulloblastoma | 0.825 |
| 4 | SRR29022840 | — | A | 0.823 |
| 5 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.821 |
| 6 | R187 | — | — | 0.818 |
| 7 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.815 |
| 8 | MNG523 | — | — | 0.812 |
| 9 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.810 |
| 10 | DRR168538 | — | — | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.441 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.401 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.397 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.392 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.339 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.332 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.317 | Idelalisib | — uncovered |
| COAGULATION | 0.272 | Binimetinib | — uncovered |
| COMPLEMENT | 0.241 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.237 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.232 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.228 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.201 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.162 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.147 | Inavolisib | — uncovered |
| APOPTOSIS | 0.133 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.131 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.114 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.112 | Inavolisib | — uncovered |